Quick answer: "Reta" is the common shorthand for retatrutide, an investigational peptide that activates three receptors at once: GIP, GLP-1 and glucagon. It was developed by Eli Lilly under the code LY3437943 and is not an approved product. Outside the manufacturer's own programme it is supplied only as a research compound, and the way to judge any supplier is by documentation: a published certificate of analysis, measured HPLC purity, and endotoxin and sterility data.
What does "reta" mean?
Search for the compound and you will see three names used interchangeably: retatrutide, reta, and "reta peptide". They all refer to the same molecule. Retatrutide is the nonproprietary name. "Reta" is simply community shorthand, in the same way that "tirz" is used for tirzepatide and "sema" for semaglutide. Some suppliers also sell it under a house brand name, which can make comparing listings harder than it should be, so the first habit worth building is to match every listing back to the compound name and the molecular profile.
The name itself describes the pharmacology. The "-tide" ending marks a peptide, and the earlier names in the family, semaglutide and tirzepatide, describe a one-receptor and a two-receptor agonist. Retatrutide extends the pattern to three receptors, which is why articles describe it as a "triple agonist".
Where retatrutide comes from
Retatrutide was designed by Eli Lilly and is listed in the literature as LY3437943. It belongs to the incretin and glucagon-family peptide analogs that have been studied for more than a decade. The published design papers describe a single peptide chain engineered to engage the GIP receptor, the GLP-1 receptor and the glucagon receptor, with modifications that extend its circulating half-life in animal models, including a fatty-diacid side chain attached through a linker.
That design history matters for a practical reason. A long, chemically modified peptide with a lipid side chain is harder to synthesize and purify than a short unmodified peptide. Yields are lower, impurity profiles are more complex, and the gap between a well-made and a poorly made batch is wide. This is the main reason documentation carries so much weight with this compound.
The receptor profile in plain terms
Each of the three receptors sits on a different branch of metabolic signalling in preclinical work. The GLP-1 receptor is the best known; it is the target of semaglutide. The GIP receptor is the second incretin receptor and is the second target of tirzepatide. The glucagon receptor adds a third axis, and in animal models it has been studied for its role in energy expenditure and hepatic lipid handling.
Published in vitro characterization describes retatrutide as active at all three receptors, with relative potency favouring the GIP receptor over the GLP-1 and glucagon receptors. Researchers use that balance as a reference point when they compare it with single and dual agonists in the same assay. For a side-by-side look at how the molecules differ at the receptor level, see our retatrutide vs tirzepatide comparison and the broader four-compound comparison.
For the mechanism in more depth, our mechanism of action article walks through the signalling steps, and the structure and synthesis article covers how the peptide is made.
Why you will see it sold as a research compound
Retatrutide has not been approved by any regulator. Material sold outside the originator's clinical programme is therefore labelled for laboratory research only, which means in vitro assays, cell models and other non-human preclinical work. It is not a drug, food or supplement, and nothing in this guide is guidance for use in people or animals.
That legal position is also why the quality conversation is so important. With no pharmacopoeial standard to fall back on, the buyer is relying on the supplier's own testing. Two vials with the same label can differ widely in actual peptide content and in impurities. A research result is only as reliable as the material behind it.
What to look for in a retatrutide listing
A checklist works better than a gut feeling. When you evaluate any reta listing, work through these points before you compare anything else.
- A real certificate of analysis for the lot. It should name the lot code, the test date and the laboratory, and show a measured purity figure rather than only a specification limit. Read our guide on how to read a COA if the layout is unfamiliar.
- HPLC purity. Chromatographic purity is the headline number, and the chromatogram itself should be attached. Understanding HPLC purity explains what the trace tells you.
- Identity and content. Purity says how much of the sample is the target peptide; it does not say how much peptide is in the vial. Look for a measured quantity.
- Endotoxin and sterility. For cell-based work these matter as much as purity, because endotoxin can distort a cell assay on its own.
- Verifiable origin. The best certificates can be checked against the laboratory's own records. Ours can be verified on the Accumark Labs site using the sample code printed on each report.
Our wider advice on picking a supplier is in how to choose a research peptide supplier, and the narrower sourcing checklist for this compound is in where to buy retatrutide.
What affects the price of research-grade reta
People search for "reta price" because the spread between listings is large, and it helps to understand why. The cost of a vial is driven by a handful of things that have little to do with marketing.
First, synthesis. A modified peptide of this length needs many coupling steps, and each step compounds yield loss. Second, purification. Reaching high chromatographic purity means discarding impure fractions, which raises the cost per usable milligram. Third, vial size: a 20 mg vial and a 10 mg vial do not cost twice or half of one another because fixed handling and testing costs are spread differently. Fourth, testing. Independent HPLC, endotoxin and sterility analysis costs real money per lot, and a supplier that skips it can price lower.
The practical takeaway is that the lowest price is a signal to look harder at the documentation, not a reason to be pleased. A price far below the rest of the market usually means a shortcut somewhere in synthesis, purification or testing.
Storage and handling at a glance
Research peptides of this type are supplied as a lyophilized powder, which is the most stable form. General laboratory practice is to keep the sealed vial refrigerated, protect it from light, heat and moisture, and avoid repeated temperature cycling. Once a vial has been reconstituted for an assay, stability falls and it should be handled as a short-lived working solution. Our storage and stability article and the reconstitution and handling guide cover the details, and the calculator guide helps with concentration arithmetic for assay design.
What V8 Peptides publishes for retatrutide
We supply retatrutide as 10 mg and 20 mg research vials. A certificate of analysis from Accumark Labs is published for the 20 mg lot on our COA page, including measured purity, content, endotoxin and PCR sterility results. A certificate for the 10 mg size is not published yet; we have requested one and will post it when it arrives. We would rather say that plainly than imply coverage we do not have.
Frequently asked questions
Is "reta" the same as retatrutide?
Yes. Reta is shorthand for retatrutide, and "reta peptide" refers to the same compound. Be aware that some suppliers use their own brand names for it, so match listings by compound name and receptor profile.
Who developed retatrutide?
Eli Lilly developed it, and the literature refers to it as LY3437943. It has not been approved by regulators, and any material sold for research is for laboratory use only.
What makes it different from semaglutide and tirzepatide?
In the published pharmacology, semaglutide acts on the GLP-1 receptor, tirzepatide on the GIP and GLP-1 receptors, and retatrutide on GIP, GLP-1 and glucagon receptors. That third receptor is the main distinction.
Why do prices vary so much?
Synthesis yield, purification effort, vial size and independent testing all change the real cost. Very low prices often point to a shortcut in one of those steps.
What should a retatrutide COA show?
A lot code, test date, laboratory name, measured HPLC purity with the chromatogram, measured content, and endotoxin and sterility results. Ideally you can verify the report with the laboratory.
How is the lyophilized powder stored?
General practice is refrigeration of the sealed vial, away from light, heat and moisture. See our storage and stability article for specifics.
Does V8 Peptides have a COA for every size?
No. A certificate is published for the 20 mg lot. We have requested one for the 10 mg size and will publish it when it arrives.
Is this guide advice for use in people?
No. Retatrutide is an unapproved investigational compound, and V8 Peptides supplies it for laboratory research only.
Where to go next
If you are comparing reta with its relatives, start with the retatrutide research overview and the research FAQ. To see the certificates we publish and verify them yourself, visit the COA page.
References
- Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metabolism. 2022;34(9):1234-1247.
- Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. New England Journal of Medicine. 2023;389:514-526.
- Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532.
For laboratory research use only. Not for human or animal consumption. Not a drug, food or cosmetic. This article is educational and describes published research; it makes no claims about outcomes in people or animals.